Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 164

1.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

Antonia SJ, Balmanoukian A, Brahmer J, Ou SI, Hellmann MD, Kim SW, Ahn MJ, Kim DW, Gutierrez M, Liu SV, Schöffski P, Jäger D, Jamal R, Jerusalem G, Lutzky J, Nemunaitis J, Calabro L, Weiss J, Gadgeel S, Bhosle J, Ascierto PA, Rebelatto MC, Narwal R, Liang M, Xiao F, Antal J, Abdullah S, Angra N, Gupta AK, Khleif SN, Segal NH.

J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30475-7. doi: 10.1016/j.jtho.2019.06.010. [Epub ahead of print]

PMID:
31228626
2.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS.

Lung Cancer. 2019 Jul;133:96-102. doi: 10.1016/j.lungcan.2019.05.011. Epub 2019 May 11.

PMID:
31200835
3.

A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma.

van Brummelen EMJ, Levchenko E, Dómine M, Fennell DA, Kindler HL, Viteri S, Gadgeel S, López PG, Kostorov V, Morgensztern D, Orlov S, Zauderer MG, Vansteenkiste JF, Baker-Neblett K, Vasquez J, Wang X, Bellovin DI, Schellens JHM, Yan L, Mitrica I, DeYoung MP, Trigo J.

Invest New Drugs. 2019 May 7. doi: 10.1007/s10637-019-00783-7. [Epub ahead of print]

PMID:
31065954
4.

Profiling the Mutational Landscape in Known Driver Genes and Novel Genes in African American Non-Small Cell Lung Cancer Patients.

Lusk CM, Watza D, Dyson G, Craig D, Ratliff V, Wenzlaff AS, Lonardo F, Bollig-Fischer A, Bepler G, Purrington K, Gadgeel S, Schwartz AG.

Clin Cancer Res. 2019 Apr 12. doi: 10.1158/1078-0432.CCR-18-2439. [Epub ahead of print]

PMID:
30979741
5.

Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer.

Hawkins PG, Sun Y, Dess RT, Jackson WC, Sun G, Bi N, Tewari M, Hayman JA, Kalemkerian GP, Gadgeel SM, Lawrence TS, Haken RKT, Matuszak MM, Kong FS, Schipper MJ, Jolly S.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1635-1643. doi: 10.1007/s00432-019-02903-5. Epub 2019 Mar 28.

PMID:
30923943
6.

Phase II Trial of Cabozantinib Plus Erlotinib in Patients With Advanced Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer With Progressive Disease on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A California Cancer Consortium Phase II Trial (NCI 9303).

Reckamp KL, Frankel PH, Ruel N, Mack PC, Gitlitz BJ, Li T, Koczywas M, Gadgeel SM, Cristea MC, Belani CP, Newman EM, Gandara DR, Lara PN Jr.

Front Oncol. 2019 Mar 11;9:132. doi: 10.3389/fonc.2019.00132. eCollection 2019.

7.

Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.

Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT.

J Thorac Oncol. 2019 Mar 20. pii: S1556-0864(19)30210-2. doi: 10.1016/j.jtho.2019.03.007. [Epub ahead of print]

8.

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Shaw AT, Solomon BJ, Besse B, Bauer TM, Lin CC, Soo RA, Riely GJ, Ou SI, Clancy JS, Li S, Abbattista A, Thurm H, Satouchi M, Camidge DR, Kao S, Chiari R, Gadgeel SM, Felip E, Martini JF.

J Clin Oncol. 2019 Jun 1;37(16):1370-1379. doi: 10.1200/JCO.18.02236. Epub 2019 Mar 20.

PMID:
30892989
9.

Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non-small-cell lung cancer: KEYNOTE-021 cohorts D and H.

Gubens MA, Sequist LV, Stevenson JP, Powell SF, Villaruz LC, Gadgeel SM, Langer CJ, Patnaik A, Borghaei H, Jalal SI, Fiore J, Saraf S, Raftopoulos H, Gandhi L.

Lung Cancer. 2019 Apr;130:59-66. doi: 10.1016/j.lungcan.2018.12.015. Epub 2018 Dec 17.

PMID:
30885353
10.

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Schoenfeld AJ, Arbour KC, Rizvi H, Iqbal AN, Gadgeel SM, Girshman J, Kris MG, Riely GJ, Yu HA, Hellmann MD.

Ann Oncol. 2019 May 1;30(5):839-844. doi: 10.1093/annonc/mdz077.

PMID:
30847464
11.

Cancer Site and Adverse Events Induced by Immune Checkpoint Inhibitors: A Retrospective Analysis of Real-life Experience at a Single Institution.

Sukari A, Nagasaka M, Alhasan R, Patel D, Wozniak A, Ramchandren R, Vaishampayan U, Weise A, Flaherty L, Jang H, Kim S, Gadgeel S.

Anticancer Res. 2019 Feb;39(2):781-790. doi: 10.21873/anticanres.13175.

PMID:
30711957
12.

Phase 1b/2 Randomized Study of MEDI-575 in Combination With Carboplatin Plus Paclitaxel Versus Carboplatin Plus Paclitaxel Alone in Adult Patients With Previously Untreated Advanced Non-Small-Cell Lung Cancer.

Wheatley-Price P, Gadgeel S, Takahashi T, Li X, Dar M, Blumenschein GR Jr.

Clin Lung Cancer. 2019 May;20(3):e362-e368. doi: 10.1016/j.cllc.2018.11.012. Epub 2018 Nov 29.

PMID:
30685114
13.

Quantitative Imaging Markers of Lung Function in a Smoking Population Distinguish COPD Subgroups with Differential Lung Cancer Risk.

Lusk CM, Wenzlaff AS, Watza D, Sieren JC, Robinette N, Walworth G, Petrich M, Neslund-Dudas C, Flynn MJ, Song T, Spizarny D, Simoff MJ, Soubani AO, Gadgeel S, Schwartz AG.

Cancer Epidemiol Biomarkers Prev. 2019 Apr;28(4):724-730. doi: 10.1158/1055-9965.EPI-18-0886. Epub 2019 Jan 14.

PMID:
30642838
14.

Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.

Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L.

Lung Cancer. 2019 Feb;128:105-112. doi: 10.1016/j.lungcan.2018.12.017. Epub 2018 Dec 19.

PMID:
30642441
15.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.

Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A.

J Thorac Oncol. 2019 Mar;14(3):553-559. doi: 10.1016/j.jtho.2018.11.028. Epub 2018 Dec 4.

PMID:
30529597
16.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V.

Lung Cancer. 2018 Nov;125:273-281. doi: 10.1016/j.lungcan.2018.08.019. Epub 2018 Aug 25.

PMID:
30429032
17.

Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.

Hong DS, LoRusso P, Hamid O, Janku F, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL.

Clin Cancer Res. 2019 Apr 15;25(8):2403-2413. doi: 10.1158/1078-0432.CCR-18-1341. Epub 2018 Nov 13.

PMID:
30425090
18.

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.

Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT.

Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Erratum in: Lancet Oncol. 2019 Jan;20(1):e10.

PMID:
30413378
19.

Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling.

Qin A, Johnson A, Ross JS, Miller VA, Ali SM, Schrock AB, Gadgeel SM.

J Thorac Oncol. 2019 Jan;14(1):54-62. doi: 10.1016/j.jtho.2018.09.014. Epub 2018 Sep 26.

PMID:
30267839
20.

Immune Checkpoint Inhibitors in the Management of Lung Cancer.

Zimmermann S, Peters S, Owinokoko T, Gadgeel SM.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:682-695. doi: 10.1200/EDBK_201319. Review.

PMID:
30231367
21.

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.

Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR.

Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405.

22.

Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.

Gadgeel SM.

Curr Treat Options Oncol. 2018 Sep 10;19(11):53. doi: 10.1007/s11864-018-0568-3. Review.

PMID:
30203184
23.

24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer.

Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L.

J Thorac Oncol. 2019 Jan;14(1):124-129. doi: 10.1016/j.jtho.2018.08.004. Epub 2018 Aug 21.

PMID:
30138764
24.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Oct 1;29(10):2143. doi: 10.1093/annonc/mdy261. No abstract available.

PMID:
30060089
25.

New onset myasthenia gravis in a patient with non small cell lung cancer treated with lorlatinib a novel anti-cancer agent.

Desai A, Sriwastava S, Gadgeel SM, Lisak RP.

J Neurol Sci. 2018 Sep 15;392:100-101. doi: 10.1016/j.jns.2018.06.024. Epub 2018 Jul 2. No abstract available.

PMID:
30031992
26.

Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer.

Ou SI, Socinski MA, Gadgeel S, Gandhi L, West H, Chiappori AA, Cohen V, Riely GJ, Smoljanovic V, Bordogna W, Wright E, Debusk K, Zeaiter A, Shaw AT.

ESMO Open. 2018 Jul 12;3(5):e000364. doi: 10.1136/esmoopen-2018-000364. eCollection 2018.

27.

Association of ERBB Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma: Secondary Analysis of the LUX-Lung 8 Randomized Clinical Trial.

Goss GD, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, Göker E, Georgoulias V, Li W, Guclu S, Isla D, Min YJ, Morabito A, Ardizzoni A, Gadgeel SM, Fülöp A, Bühnemann C, Gibson N, Krämer N, Solca F, Cseh A, Ehrnrooth E, Soria JC.

JAMA Oncol. 2018 Sep 1;4(9):1189-1197. doi: 10.1001/jamaoncol.2018.0775.

28.

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer.

Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F.

J Thorac Oncol. 2018 Aug;13(8):1156-1170. doi: 10.1016/j.jtho.2018.04.039. Epub 2018 May 17. Erratum in: J Thorac Oncol. 2018 Nov;13(11):1800.

PMID:
29777823
29.

Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC).

Gadgeel SM, Pennell NA, Fidler MJ, Halmos B, Bonomi P, Stevenson J, Schneider B, Sukari A, Ventimiglia J, Chen W, Galasso C, Wozniak A, Boerner J, Kalemkerian GP.

J Thorac Oncol. 2018 Sep;13(9):1393-1399. doi: 10.1016/j.jtho.2018.05.002. Epub 2018 Jul 17.

PMID:
29775808
30.

Using Radiolabeled 3'-Deoxy-3'-18F-Fluorothymidine with PET to Monitor the Effect of Dexamethasone on Non-Small Cell Lung Cancer.

McHugh CI, Thipparthi MR, Lawhorn-Crews JM, Polin L, Gadgeel S, Akoury J, Mangner TJ, Douglas KA, Li J, Ratnam M, Shields AF.

J Nucl Med. 2018 Oct;59(10):1544-1550. doi: 10.2967/jnumed.117.207258. Epub 2018 Apr 19.

31.

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators.

N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.

32.

Comparing Treatment Strategies for Stage I Small-cell lung Cancer.

Paximadis P, Beebe-Dimmer JL, George J, Schwartz AG, Wozniak A, Gadgeel S.

Clin Lung Cancer. 2018 Sep;19(5):e559-e565. doi: 10.1016/j.cllc.2018.03.017. Epub 2018 Mar 23.

33.

The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Gadgeel SM.

Future Oncol. 2018 Aug;14(18):1875-1882. doi: 10.2217/fon-2018-0027. Epub 2018 Mar 14. Review.

PMID:
29536761
34.

Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology.

Gridelli C, Baas P, Barlesi F, Ciardiello F, Crinò L, Felip E, Gadgeel S, Papadimitrakopoulou V, Paz-Ares L, Planchard D, Perol M, Hanna N, Sgambato A, Casaluce F, de Marinis F.

Clin Lung Cancer. 2018 Jul;19(4):301-314. doi: 10.1016/j.cllc.2017.12.010. Epub 2017 Dec 22. Review.

PMID:
29396237
35.

Improved EGFR mutation detection using combined exosomal RNA and circulating tumor DNA in NSCLC patient plasma.

Krug AK, Enderle D, Karlovich C, Priewasser T, Bentink S, Spiel A, Brinkmann K, Emenegger J, Grimm DG, Castellanos-Rizaldos E, Goldman JW, Sequist LV, Soria JC, Camidge DR, Gadgeel SM, Wakelee HA, Raponi M, Noerholm M, Skog J.

Ann Oncol. 2018 Mar 1;29(3):700-706. doi: 10.1093/annonc/mdx765.

36.

Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer.

Nagasaka M, Gadgeel SM.

Expert Rev Anticancer Ther. 2018 Jan;18(1):63-70. doi: 10.1080/14737140.2018.1409624. Epub 2017 Nov 26. Review.

PMID:
29168933
37.

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC.

Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI.

Br J Cancer. 2018 Jan;118(1):38-42. doi: 10.1038/bjc.2017.395. Epub 2017 Nov 16.

38.

Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results (SEER) Data.

Thakur MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, Beebe-Dimmer JL, Wozniak AJ.

J Thorac Oncol. 2018 Jan;13(1):46-53. doi: 10.1016/j.jtho.2017.09.1964. Epub 2017 Oct 5.

39.
40.

Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patients.

Ou SI, Horn L, Cruz M, Vafai D, Lovly CM, Spradlin A, Williamson MJ, Dagogo-Jack I, Johnson A, Miller VA, Gadgeel S, Ali SM, Schrock AB.

Lung Cancer. 2017 Sep;111:61-64. doi: 10.1016/j.lungcan.2017.07.006. Epub 2017 Jul 11.

41.

Retreatment With Osimertinib Following Pneumonitis.

Nagasaka M, Gadgeel SM.

Clin Lung Cancer. 2018 Jan;19(1):e53-e55. doi: 10.1016/j.cllc.2017.06.017. Epub 2017 Jul 6. No abstract available.

PMID:
28736180
42.

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.

Felip E, Hirsh V, Popat S, Cobo M, Fülöp A, Dayen C, Trigo JM, Gregg R, Waller CF, Soria JC, Goss GD, Gordon J, Wang B, Palmer M, Ehrnrooth E, Gadgeel SM.

Clin Lung Cancer. 2018 Jan;19(1):74-83.e11. doi: 10.1016/j.cllc.2017.06.002. Epub 2017 Jun 23.

43.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT.

J Thorac Oncol. 2017 Oct;12(10):1552-1560. doi: 10.1016/j.jtho.2017.06.070. Epub 2017 Jul 6.

44.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S.

Eur J Cancer. 2017 Sep;82:27-33. doi: 10.1016/j.ejca.2017.05.019. Epub 2017 Jul 10.

PMID:
28646771
45.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators.

N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.

46.

Evaluation of the VeriStrat® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study.

Gadgeel S, Goss G, Soria JC, Felip E, Georgoulias V, Lu S, Cobo M, Syrigos K, Lee KH, Göker E, Guclu SZ, Isla D, Morabito A, Dupuis N, Bühnemann C, Krämer N, Solca F, Ehrnrooth E, Ardizzoni A.

Lung Cancer. 2017 Jul;109:101-108. doi: 10.1016/j.lungcan.2017.05.010. Epub 2017 May 11.

47.

Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer.

Gadgeel SM.

Am Soc Clin Oncol Educ Book. 2017;37:630-639. doi: 10.14694/EDBK_175188. Review.

48.

Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer.

Gadgeel SM.

Curr Treat Options Oncol. 2017 Jun;18(6):36. doi: 10.1007/s11864-017-0479-8. Review.

PMID:
28534251
49.

Histologic Transformation in NSCLC with PD-1 therapy.

Nagasaka M, Pansare RS, Abdulfatah E, Guan H, Tranchida P, Gadgeel SM.

J Thorac Oncol. 2017 Sep;12(9):e133-e134. doi: 10.1016/j.jtho.2017.04.026. Epub 2017 May 10. No abstract available.

50.

Optimal front-line ALK (anaplastic lymphoma kinase) directed therapy.

Gadgeel SM.

Lung Cancer. 2017 Jul;109:147-148. doi: 10.1016/j.lungcan.2017.03.008. Epub 2017 Mar 20. No abstract available.

PMID:
28365051

Supplemental Content

Loading ...
Support Center